Skip to content
Screener

Perspective Therapeutics CATX Q2 2025 earnings

Reported August 13, 2025 · Before market open

Revenue$234.0KBeat by $59.4K
EPS-$0.30In line
Revenue estimate$174.6K
EPS estimate-$0.30

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$62.1K
EPS estimate-$0.24

Financials

Q2 2025

Income statement

See full
Operating income-$24.0M-68.5%
Net income-$21.5M-83.6%
EPS (diluted)-$0.29-61.1%

Balance sheet

See full
Cash & equivalents$28.8M-88.6%
Total debt$3.5M-8.0%
Total equity$265.7M-22.1%
Total assets$310.7M-19.5%

Cash flow

See full
Operating cash flow-$20.0M-124%
CapEx$1.0M+1.1%
Free cash flow-$21.0M-112%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$283.55M-57.8%
Enterprise value$258.22M-39.1%

Returns & leverage

See full
Return on equity-31.3%+7.5pp
Debt / equity0×0.0×
Current ratio15.1×-12.6×

FAQ

When did Perspective Therapeutics report Q2 2025 earnings?
Perspective Therapeutics (CATX) reported Q2 2025 earnings on August 13, 2025 before market open.
What were Perspective Therapeutics's Q2 2025 revenue and EPS?
Perspective Therapeutics reported revenue of $234.0K and eps of $-0.30 for Q2 2025.
Did Perspective Therapeutics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $174.6K by $59.4K. EPS beat the consensus estimate of $-0.30 by $0.00.
How did Perspective Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 55.5% from $526.0K a year earlier and eps declined 76.5% from $-0.17.
Where can I find Perspective Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-107609) and the 10-Q periodic report (0000950170-25-107619) directly on SEC EDGAR. The filing index links above go to sec.gov.